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Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder. Considering that XP patients have a defect of the nucleotide
excision repair (NER) pathway which enables them to repair DNA damage caused by UV light, they have an increased risk of
developing skin and eyes cancers. In the present study, we investigated the involvement of the prevalent XPA and XPC genes
mutations—nonsense mutation (c.682C>T, p.Arg228X) and a two-base-pair (2 bp) deletion (c.1643 1644delTG or p.Val548Ala
fsX25), respectively—in 19 index cases from 19 unrelated families in the West of Algeria. For the genetic diagnosis of XPA gene,
we proceeded to PCR-RFLP. For the XPC gene, we validated a routine analysis which includes a specific amplification of a short
region surrounding the 2 bp deletion using a fluorescent primer and fragment sizing (GeneScan size) on a sequencing gel. Among
the 19 index cases, there were 17 homozygous patients for the 2 bp deletion in theXPC gene and 2 homozygous patients carrying the
nonsense XPAmutation. Finally, XPC appears to be the major disease-causing gene concerning xeroderma pigmentosum in North
Africa.The use of fragment sizing is the simplest method to analyze this 2 bp deletion for the DNA samples coming from countries
where the mutation c.1643 1644delTG of XPC gene is prevalent.
1. Introduction
Xeroderma pigmentosum (XP, OMIM 278700–278780) is a
rare inherited autosomal recessive disorder characterized by
an inability to repair DNA damage caused by ultraviolet
(UV) light [1, 2] which induces skin cancers [3, 4] and other
skin manifestations including poikiloderma, skin atrophy,
telangiectasia, actinic keratoses, angiomas, and keratoacan-
thomas. XP patientsmay also have ocularmanifestations, like
photophobia, conjunctivitis, keratitis, ectropion, and entro-
pion [5]. Neurologic symptoms such as mental deterioration,
sensorineural deafness, hyporeflexia, and ataxia are found in
severe forms of the disease [1, 6]. XP affects both sexes equally
[7] with an incidence of 1/1 000 000 births in the USA and
Europe [8], 1/20 000–100 000 in Japan [9, 10], and 1/10 000–
30 000 in North Africa [11–14].
XP is found in all races worldwide and caused by defect
in seven complementation groups (XP-A to XP-G) involved
Hindawi Publishing Corporation
BioMed Research International
Volume 2016, Article ID 2180946, 7 pages
http://dx.doi.org/10.1155/2016/2180946
2 BioMed Research International
in NER system [15]. Four complementation groups (XP-
A, XP-B, XP-D, and XP-G) exhibit neurological manifesta-
tions [16]. XP-C, XP-E, and XP-F patients rarely develop
neurological disorders [17, 18]. Two different mechanisms
of DNA repair can be distinguished: the Global Genome
Repair (GGR) recognizes and removes lesions throughout the
entire genome [19] while the Transcription-Coupled Repair
(TCR) is specific to DNA damage occurring at transcribed
strands of active genes [20]. Twenty per cent of XP patients
present a normal NER system (XP-V) but a defective DNA
polymerase eta (𝜂) gene (POLH) [21]. XP-C and XP-A are the
most prevalent groups in North Africa and Southern Europe
[22, 23].
Xeroderma pigmentosum complementation group C
(MIM ID #278720) is caused by mutations in the XPC gene
(MIMID∗613208) and the most frequent mutation is a
2 bp deletion (c.1643 1644delTG, p.Val548AlafsX25) [13].
This gene is located on chromosome 3 (3p25) and contains
16 exons encoding for xeroderma pigmentosum group C
(XPC) protein (GenBank accession number AC090645).
This protein recognizes the damaged bases at the beginning
of GGR pathway and it binds to HR23B to form the stable
XPC-HR23B complex [24], which leads to the recruitment
of TFIIH involved in the subsequent unwinding of the DNA
double helix in concert with the proteins XPG, XPA, and
replication protein A (RPA) [25].
Xeroderma pigmentosum complementation group A
(MIM ID #278700) is caused by mutations in the XPA
gene (MIMID∗ 611153) and the most frequent mutation is a
nonsense mutation (c.682C>T, p.Arg228X) [26]. This gene
is located on chromosome nine (9q34.1) [27] and consists
of 6 exons that encodes for a 273-amino-acid Zn2+-finger
protein [28]. The XPA protein plays a crucial role in both
GGR and TCR pathways. The complex XPA-RPA provides
the verification of the lesion and the binding to the single
stranded DNA, so that the NER factors stay positioned
around the lesion [29].
In the present study, we aimed to screen and detect for the
first time themost commonmutations inXPA andXPC genes
presented in unrelated XP patients from the West of Algeria
with clinical features of XP. Knowledge of these mutations is
important for genetic counseling. Here, we used a new useful
tool for rapid genotyping of the prevalent mutation of XPC
gene.
2. Materials and Methods
2.1. Subjects. In this study, we collected 58 DNA samples
from 19 unrelated XP families originated from Western
Algeria. Among them, there were 19 index cases, 31 parents,
and 8 siblings suffering from XP. Recruitment of patients
with clinical diagnoses of XP disorder was provided at the
OphthalmologyDepartment, Children’sHospital of Canastel,
Oran (Algeria).
2.2. Methods. Informed signed consent for genetic inves-
tigation was obtained from all patients or from their par-
ents in case of minors. Families were interviewed using a
structured questionnaire to collect information about family
history, consanguinity, affected members, and associated
diseases. The clinical data of XP patients are summarized in
Table 1.
2.2.1. DNA Extraction. DNA was isolated from peripheral
blood leukocyte using STRATAGENE kit reagents (Agi-
lent Technologies Division) according to the manufacturer’s
instructions at the Laboratory of Molecular and Cellular
Genetics.
2.2.2. XPA Genotyping. To detect the previously reported
nonsense mutation in exon 6 of the XPA gene (p.Arg228X),
we used the following primers for the PCR reaction: forward
primer 5󸀠-TACATGGCTGAAAGCTTGAT-3󸀠 and reverse
primer 5󸀠-GGG TTT CAT TCA TCT ATG-3󸀠. The fragments
were amplified by PCR in a volume of 50 𝜇L containing
50 ng of DNA, 1x PCR buffer, 0.2mM of each dNTP, 2.5mM
MgCl
2
, 10 pmol of each one of the primers, and 1U of Taq
polymerase. PCR was performed using a Primus thermal
cycler and the program included 95∘C for 10min, 35 cycles
of 95∘C for 30 s, 52∘C for 30 s, and 72∘C for 30 s. The cycles
were followed by a final step of 72∘C for 5min. The PCR
products were then subjected to RFLP analysis. Digestion
of the PCR products was carried out according to the
manufacturer’s instructions. 5 𝜇L of the PCR products was
digested overnight with 5U of HphI at 37∘C. The digestion
products were separated on 2% agarose gel. The restriction
enzyme HphI (New England Biolabs, USA) was used to
distinguish the R228Xmutation in which the gain of an HphI
restriction site occurs in the mutant allele. The wild-type (C)
has two bands (320 bp and 31 bp fragments); however, the
mutant allele (T) has three bands (245 bp, 75 bp, and 31 bp
fragments).
2.2.3. XPC Genotyping. Specific amplification of the short
region surrounding the deletion of two bases in exon 9 of the
XPC genewas provided by two primers: a fluorescent forward
primer 5󸀠-(6FAM)GCATAGCTGGTATAGACCAG-3󸀠 and a
reverse primer 5󸀠-gtttcttTCGTACCTCTGTGTGACATC-3󸀠,
which generates a fragment of 194 bp (normal allele) or 192 bp
(deleted allele). PCRwas performed in Primus thermal cycler
using a final volume of 50 𝜇L containing 100 ng of DNA,
1x PCR buffer, 0.2mM dNTPs, 2.5mM MgCl
2
, 0.2 𝜇M of
each one of the primers, and 1.25U of Taq polymerase.
PCR was performed as follows: 95∘C for 10min, 25 cycles
of 94∘C for 30 s, 30 s at 60∘C, 30 s at 72∘C, and a final
step at 72∘C for 5min. The PCR products were checked
on a 2% agarose gel. A step of purification and dilution
was ensured for the PCR product with the addition of 90%
formamide and 350 Rox marker in the loading dye. The
fluorescent PCR products were separated on an automatic
sequencer (ABI 3500, Applied Biosciences). Allele calling
by fragment size analysis was performed with the aid of
GeneScan software (Applied Biosciences). We also amplified
the same exon 9 of XPC with different primers and sequenc-
ing products were analyzed by SeqScape software (Applied
Biosciences).
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Sex Age Age of onset(months) Consanguinity
Clinical symptoms
Photophobia Skin lesions Tumors Neurologicalabnormalities
XP01 Northwest M 17 12 1stD + + ++ −
XP02 Northwest F 12 7 1stD + + +++ −
XP03 Northwest F 7 2 1stD + + − +
XP04 Northwest F 15 12 1stD + + + −
XP05 Northwest M 8 3 1stD + + + +
XP06 Northwest M 11 24 2ndD + + ++ −
XP07 Northwest M 15 12 1stD + + +++ −
XP08 Northwest F 10 36 1stD + + + −
XP09 Northwest M 14 8 1stD + + +++ −
XP10 Northwest F 13 36 1stD + + +++ −
XP11 Northwest M 23 12 1stD + + +++ −
XP12 Middle West M 4 24 1stD + + − −
XP13 Northwest M 10 12 1stD + + − −
XP14 Northwest F 4 12 1stD + + + −
XP15 Northwest F 6 18 1stD + + ++ −
XP16 Northwest M 15 36 1stD + + +++ −
XP17 Middle West M 25 12 AC + + +++ −
XP18 Southwest F 6 24 1stD + + − −
XP19 Middle West F 6 11 2ndD + + − −
1stD: consanguinity first degree; 2ndD: consanguinity second degree; AC: absence of consanguinity.
−: absence of clinical symptoms; +: presence of clinical symptoms.
3. Results
3.1. Clinical Findings. All investigated patients presented
photophobia, skin photosensitivity, poikiloderma, and xero-
dermawith amean age of 11 years.We registered consanguin-
ity in 94.73% (18/19) of families. Among them, 88.89%were of
the first degree and 11.11% of the second degree. XP symptoms
had begun at amean age of 16.5months (range 2–36months).
Skin cancer was described in 73.68% of patients and ocular
cancer was reported in 63.15%. Sex ratio (M/F) was 1.1, with
different clinical presentations. Neurological symptoms were
observed in 2 out of 19 patients. Besides data indicated in
Table 1, we had also registered familialmedical history, height,
weight, and different common parameters.
3.2. Genotyping of XP-A Patients by PCR-RFLP and DNA
Visualization by Gel Electrophoresis. Two XP patients (XP03
and XP05; see Table 1) who presented a clinical diagnosis of
XP-A (association of different symptoms including neurolog-
ical ones) were genotyped for the prevalent mutation XPA
(p.Arg228X) in Pellegrin Hospital (Bordeaux). To detect the
nonsense mutation in exon 6 of the XPA gene, we examined
the HphI RFLP in the amplified exon 6 DNA fragments
(351 bp).TheC-to-T transition in exon 6 leads to a conversion
of an arginine residue (CGA codon) to a stop codon (TGA)
at amino acid 228. DNA from normal subjects who have a
normal XPA allele gives a profile of two bands (320 bp and
31 bp fragments). In contrast, DNA fromaXPpatient with the
homozygousmutation in exon 6 gives a profile of three bands
(245 bp, 75 bp, and 31 bp fragments) caused by the creation
of a new cleavage site for HphI in the 320 bp fragment by
the nonsense mutation. After loading on 2% agarose gel, we
found that both patients checked for the R228X mutation
presented a profile homozygous for the mutant allele (T/T).
Their parents were heterozygous carriers (C/T) with a profile
of four bands (320 bp, 245 bp, 75 bp, and 31 bp fragments),
confirming that these two patients are homozygous for the
nonsense mutation at codon 228 and belong to the XP-A
subclass.
3.3. Genotyping of XP-C Patients by Fragment Size and
Sequence Analyses. Seventeen XP patients without neurolog-
ical troubles (and their parents)were genotyped for the preva-
lent XPCmutation (c.1643 1644delTG, p.Val548AlafsX25) in
Pellegrin Hospital. The GeneScan analysis performed for all
samples tested showed three possible genotypes: wild-type
(194 bp), heterozygous (192 and 194 bp), and homozygous
(192 bp) for the deletion (Figure 1). All 17 index cases were
homozygous for the 2 bp deletion.This deletion is responsible
for a frame shift causing the occurrence of a premature stop
codon 25 residues downstream; then we checked for the
same mutation on their siblings and found that they were
also homozygous for the 2 bp deletion. These results were
confirmed by amplification of the fragment and sequencing:
the presence of the deletion was identified by the SeqScape
software (Applied Biosciences) (Figures 2 and 3).
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Figure 1: Characterization of the 2 bp deletion in exon 9 of the XPC gene. Fragment sizing analysis from electropherograms (GeneScan
software) showed three possible profiles for the c.1643 1644delTGmutation: wild-type (a); homozygous deleted (b); heterozygous (c) profile.





















































































Figure 2: The corresponding sequence in the ninth exon of the XPC gene. The deduced amino acid sequence (NP 004619.3) in single letter
code is shown below the reference sequence (NM 004628.4, highlighted in green). The 2 bp deletion is determined by a red rectangle.
4. Discussion
We report here a DNA analysis for 19 unrelated XP fam-
ilies. Our study focused on two frequent mutations, the
frame shift mutation (c.1643 1644delTG, p.Val548AlafsX25),
located in exon 9 of the XPC gene, and the nonsense
mutation (c.682C>T) in exon 6 of the XPA gene, both
already described. XPA mutations were present in 2 of 19
(10.5%) patients with the same nonsensemutation, c.682C>T
(p.Arg228X), and XPC mutations were identified in 17 of 19
(89.5%) with the common XPCmutation, c.1643 1644delTG,
present at the homozygous state in all XP-C patients. Obvi-
ously, there is a correlation between the phenotype and
genotype, which highlights the importance of the precocious
diagnosis in these patients and an early full protection against
sun-exposure to allow them to have almost a normal life.
The analysis of both parents (13 cases/19) or one parent (5
cases/19) showed that they were heterozygous carriers for the
same mutation. In addition, the eight siblings suffering from
XP were all homozygous for the frame shift mutation.
Molecular investigation of Soufir et al. [22] on 66 unre-
lated families from the Maghreb region showed that 85% of
patients had mutations in the XPC gene; among them 87%
shared the founder mutation (c.1643 1644delTG). 12% of XP
patients had mutations in the XPA gene with a frequency of
the mutation (c.682C>T) about 87.5%.
The XPA protein plays a central role in the first steps
of NER and contains specific binding sites for other NER
proteins such as DNA damage-binding protein 2 (DDB2)
and RPA [30]. Hence, the severity of clinical manifestations
decreases while the mutation moves from the N terminal
to the C terminal of the protein, with the exception of the
cases where splice sitemutations permit the synthesis of small
amount of normal protein [31]. Since the nonsense mutation
is located on the sixth, N-terminal exon, we can speculate that
most of the mRNA of the XPA gene would be produced, and
it does not affect the major function of the XPA gene [32]. Of
interest, the c.682C>Tmutation occurs outside of the impor-
tant domains such as the DNA-binding domain (exons 2–5,
residues 98–219) and the zinc-fingermotif (residues 105–129),
but the XPA-TFIIH interaction region (residues 226–273 aa)
essential for the excision reaction is lost, which explains
the defective DNA repair system [26, 33, 34]. Therefore,
the moderate phenotype of Tunisian XP-A patients may be
explained by a residual DNA-binding activity of mutant XPA
protein in comparison with the Japanese XP-A patients who
had a splicing mutation at intron 3 at the homozygous state
[26, 32]. A recent study of Tunisian XP-A patients showed
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Figure 3: Sequence analysis of genomic DNA confirming the 2 bp deletion in the XPC gene. The alignment of sequences was obtained with
the SeqScape software. The black rectangle indicates the position of the 2 bp deletion. Electropherograms show the three profiles: wild-type
(a); homozygous deleted (b); heterozygous (c). For the c profile, because of the presence of both alleles, the two sequences (wild-type and
deleted) were superimposed after the deletion.
the presence of a recurrent mutation R228X with a founder
effect by haplotype analysis [26]. The R228X mutation was
described in North Africa patients [22, 26, 32, 35].
The deficient XP-C human cells lead to a reduction of the
cisplatin repair and increased mutagenesis [36]. This protein
is a major factor in damage recognition to initiate global
genome NER. The presence of the common 2 bp deletion
leads to a premature termination codon and absence of nor-
mal XPC protein [37]. Indeed, it affects interaction capacities
between XPC protein, HR23B, CETN2 (centrin-2 protein),
and TFIIH molecules, which are necessary for DNA damage
recognition [22]. The DNA repair ability was found to be
only 20% of proficient normal cells with the presence of this
previous mutation [38]. This same mutation was described
by Ben Rekaya et al. [39] in 100% of 14 XP-C families from
different regions of Tunisia and also in two other African
patients with XP [40]. Interestingly, Mahindra et al. [41]
also described the XPC mutation in two brother patients
from North Sudan. Furthermore, the molecular analysis of
24 Moroccan patients showed that 17 were homozygous for
the c.1643 1644delTG mutation [42]. Most XP-C African
patients with delTG mutation in both alleles have similar
clinical features consisting of photosensitivity, pigmentary
lesions, and early onset of skin cancer without neurological
involvement as our XP-C patients [22, 39, 41]. However, two
patients were reported to be homozygous for the delTG but
with neurological involvement [22].
Many studies showed that the mutation c.1643
1644delTG was spread in North Africa such as in Egypt,
Italy, and Spain, which attracted the eyes of the researchers
to the possibility of having the same ancestor. Soufir et al.
proved the presence of a founder effect in the Mediterranean
region using mathematical tools based on microsatellites
haplotyping. They also showed that this common ancestor
mutation was carried about 1250 years ago corresponding
to 50 generations and approximately when Muslims from
Arabia invaded Europe.
5. Conclusion
The high frequency of the founder mutation in XP patients
from North Africa simplified the molecular diagnosis. In
Algeria, the molecular investigation of XP confirmed that
XPC and XPA genes were the most frequent with the muta-
tions XPC-p.Val548AlafsX25 and XPA-R228X. Early diagno-
sis and full protection against sun-exposure are essential for
preventing skin cancer and preserving vision in XP patients
and can save lives.
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It is important to do simple screening tests in risk families
to detect heterozygous carriers for gene counseling, especially
in communities with highmarriage consanguinity.Moreover,
prenatal diagnosis is greatly simplified when the molecular
defect is easily accessible with the knowledge of the prevalent
mutation in a given population, as observed in XP-C and XP-
A patients.
Considering the efforts and costs required for the
unscheduled DNA synthesis on cultured fibroblasts, we
therefore recommend the use of DNA fragment sizing as the
simplest and faster method for screening in XP diagnosis. In
the population tested for this study, the high level of consan-
guinity, the large families with numerous siblings affected,
and a high rate of premature death lead to the conclusion
that the disease is clearly a major health concern.This simple
screening test in risk families may greatly facilitate genetic
counseling in exposed families aswell as earlymanagement of
affected patients. Furthermore, early diagnosis may improve
prognosis of the disease, with extensive protection against the
sun.
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